

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CGGACCACCA GCTGGTACTT GA

22

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GCTGCCCTAG AGGGTTTTGC TA

22

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CGAGACGGCA GAAAGCAGA

19

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GTACAAGTCC CGGGTGGTGA G

21

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ATACCTAAGA CAAGTTTGCT

20

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ATCAACCAAT AGAGTCCACC A

21

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CATCGTTATG AGTGACTGGA

20

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ACTGATGATC ACCCTCCTGC TCA

23

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGACAGGCAT TGTTCCCTGG

20

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

TAACTGTGGT TTCCATGACG

20

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

AGGTACTCTT GGTGCAGCCC

20

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGCATATAGG AACAGTCGTG CC

22

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

AGTGGACATG AAGAGCACGA A

21

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

AGCTCTGGCA CTGCTAGCGT CACTGATTTT

30

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CAGGTTTCATC GCTCAGCTCC

20

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GGCTGTCACC GCTTTCTTGG

20

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AGTGTTGGCA CTTCTGTGG

19

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

AGCATGGGAG ATGTTGGCAG C

21

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CTGGTTTAAA CTGGGCCCCAG GAGAGGAGCA

30

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

TGGAGCGAAG GTTAGTGGTC

20

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

TACCTGGCAC CTGAGTGTGG AG

22

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

AGAATTGGAT CATTTCTGAC AGGG

24

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

AGACATGGTC TTTGGCTTCA GGGTC

25

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

CAGACCAATG TGACAATTTT CCCCAAATGT

30

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CTACCTTCCA CGACTTCACC

20

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

AAGTCTTTTA TAAGGCTCCG GC

22

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

AGGCCATGGT GTCATCCATC

20

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

AGAGAGAGAG TAGGTCCGCG G

21

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Epstein-Barr virus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

CCAATGGGGG AGGAGAGACC AAGACCAATA

30



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/70	A3	(11) International Publication Number: WO 99/45155 (43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/EP99/01392 (22) International Filing Date: 1 March 1999 (01.03.99) (30) Priority Data: 98200655.3 4 March 1998 (04.03.98) EP 98204231.9 14 December 1998 (14.12.98) EP (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): VERVOORT, Marcel, Bartolina, Hendrikus, Johannes [NL/NL]; Streefkerkstraat 77, NL-1107 LM Amsterdam (NL). VAN DEN BRULE, Adrianus, Johannes, Christiaan [NL/NL]; Boekweitdonk 8, NL-1112 JJ Diemen (NL). MIDDELDORP, Jaap, Michiel [NL/NL]; Staringstraat 151, NL-5343 GD Oss (NL). (74) Agent: VAN GENT, M.; P.O. Box 20, NL-5340 BH Oss (NL).		(81) Designated States: AU, CA, ID, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 4 May 2000 (04.05.00)
(54) Title: OLIGONUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF EPSTEIN BARR VIRUS (EBV) NUCLEIC ACID (57) Abstract <p>The present invention is concerned with oligonucleotides that can be used as in the amplification and detection of Epstein Barr Virus (EBV) nucleic acid, in particular RNA-specific sequences. Furthermore a method for the diagnosis of EBV associated malignant and non-malignant diseases is provided. The oligonucleotides according to the present invention are specifically suited for the detection of EBV gene expression in circulating peripheral blood cells, in human (tumor) tissue samples and thin sections thereof using "in solution" amplification or "in situ" amplification techniques and in other biological samples potentially containing EBV-infected cells.</p>		

*(Referred to in PCT Gazette No. 47/1999, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Int. Patent Application No.
PCT/EP 99/01392

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEUNG ET AL.: "DETECTION OF VIRAL SEQUENCES BY INTERNALLY CALIBRATED GENE AMPLIFICATION" BIOTECHNIQUES, vol. 14, no. 5, 1993, pages 785-789, XP002076373	1,10,11, 15,16
Y	the whole document	2-4,7-9, 12,13
X	WO 93 23569 A (RIBOZYME PHARM INC) 25 November 1993 (1993-11-25)	10,11,14
Y	See EBV target sequence 18,19 and 21. the whole document	1,2,8,9, 12,13, 15,16
	— —/— —	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

7. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 February 2000

Date of mailing of the international search report

16 MARCH 2000

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer _____

Hagenmaier, S

International Application No.
PCT/EP 99/01392

BNSDOCID: <WO__9945155A3 I >

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/01392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHANG ET AL.: "TRANSCRIPTIONAL EXPRESSION OF THE VIRAL GENOME IN THE EPSTEIN-BARR VIRUS-INDUCED TAMARIN LYMPHOMA AND THE CORRESPONDING LYMPHOBLASTOID TUMOUR LINES" VIRUS RESEARCH, vol. 26, 1992, pages 153-166, XP000877165 See TABLE 2 the whole document	1-16
Y	TIERNEY ET AL.: "EPSTEIN-BARR VIRUS LATENCY IN BLOOD MONONUCLEAR CELLS: ANALYSIS OF VIRAL GENE TRANSCRIPTION DURING PRIMARY INFECTION AND IN THE CARRIER STATE" JOURNAL OF VIROLOGY, vol. 68, no. 11, November 1994 (1994-11), pages 7374-7385, XP002118061 the whole document	1-4, 7-16
Y	BROOKS ET AL.: "EPSTEIN-BARR VIRUS LATENT GENE TRANSCRIPTION IN NASOPHARYNGEAL CARCINOMA CELLS: COEXPRESSION OF EBNA1, LMP1, AND LMP2 TRANSCRIPTS" JOURNAL OF VIROLOGY, vol. 66, no. 5, 1992, pages 2689-2697, XP002118062 the whole document	1-4, 7-16
Y	BRINK ET AL.: "MULTIPRIMED cDNA SYNTHESIS FOLLOWED BY PCR IS THE MOST SUITABLE METHOD FOR EPSTEIN-BARR VIRUS TRANSCRIPT ANALYSIS IN SMALL LYMPHOMA BIOPSIES" MOL. CELL. PROBES, vol. 11, 1997, pages 39-47, XP002131581 the whole document	1-4, 7-16
Y	WEI ET AL.: "EXPRESSION AND TUMORIGENICITY OF THE EPSTEIN-BARR VIRUS BARF1 GENE IN HUMAN LOUCKES B-LYMPHOCYTE CELL LINE" CANCER RESEARCH, vol. 54, 1994, pages 1843-1848, XP002131583 the whole document	1, 2, 5, 7-16
Y	TOUITOU ET AL.: "TRANSCRIPTIONAL ANALYSIS OF THE EPSTEIN-BARR VIRUS INTERLEUKIN-10 HOMOLOGUE DURING THE LYTIC CYCLE" J. GEN. VIROL., vol. 77, 1996, pages 1163-1168, XP002131582 the whole document	1, 2, 6, 8-16
	— —/—	

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/EP 99/01392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LABRECQUE ET AL.: "EPSTEIN-BARR VIRUS IN EPITHELIAL CELL TUMORS: A BREAST CANCER STUDY" CANCER RESEARCH, vol. 55, 1995, pages 39-45, XP002131605 the whole document	1,2,8-16
A	EP 0 574 048 A (AKZO NV) 15 December 1993 (1993-12-15) the whole document	
A	WO 93 11267 A (CANCER RES INST) 10 June 1993 (1993-06-10) the whole document	
A	DE 196 27 932 A (BOEHRINGER MANNHEIM GMBH) 15 January 1998 (1998-01-15) the whole document	
A	WO 95 03415 A (WOLF HANS JOACHIM ; REISCHL UDO (DE); MOTZ MANFRED (DE)) 2 February 1995 (1995-02-02) the whole document	
A	EP 0 316 170 A (GENE GALWAY LIMITED G) 17 May 1989 (1989-05-17) the whole document	
P, X	BRINK ET AL.: "NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION, A NEW METHOD FOR ANALYSIS OF SPLICED AND UNSPLICED EPSTEIN-BARR VIRUS LATENT TRANSCRIPTS, AND ITS COMPARISON WITH REVERSE TRANSCRIPTASE" JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 11, November 1998 (1998-11), pages 3164-169, XP002118063 the whole document	1-5,7-16
T	HAYES ET AL.: "EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) TRANSCRIPTS ENCODING HOMOLOGUES TO IMPORTANT HUMAN PROTEINS IN DIVERSE EBV ASSOCIATED DISEASES" MOLECULAR PATHOLOGY, vol. 52, no. 2, April 1999 (1999-04), pages 97-103, XP000877178 the whole document	1,2,6, 8-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 99/01392

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4,7-16 (all partially)

Oligonucleotides with Seq.IDs 1-5 corresponding to the sequence of the BKRF1 reading frame spanning nucleotides 107950-109872 of EBNA-1, wherein Seq.ID 3 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

2. Claims: 1,2,8-16 (all partially)

Oligonucleotides with Seq.IDs 6-11 corresponding to the sequence of the reading frame spanning nucleotides 6629-6795 of EBER-1, wherein Seq.ID 6 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

3. Claims: 1,2,8-16 (all partially)

Oligonucleotides with Seq.IDs 12-16 corresponding to the sequence of the BNLF1 reading frame spanning nucleotides 169474-169207 of LMP-1, wherein Seq.ID 12 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

4. Claims: 1-4,7-16 (all partially)

Oligonucleotides with Seq.IDs 17-21 corresponding to the sequence of the exons 2,3,4,5,6,7 and 8 of LMP-2, wherein Seq.ID 19 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

5. Claims: 1,2,6-10 (all partially)

Oligonucleotides with Seq.IDs 27-31 corresponding to the sequence of the BCRF1 reading frame spanning nucleotides 8675-10184 of vIL10, wherein Seq.ID 30 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

6. Claims: 1,2,5,7-16 (all partially)

Oligonucleotides with Seq.IDs 22-26 corresponding to the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

sequence of the BARF1 reading frame spanning nucleotides 165504-166166, wherein Seq.ID 24 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

7. Claims: 1,2,6-16 (all partially)

Oligonucleotides with Seq.IDs 32-36 corresponding to the sequence of the BDLF2 reading frame spanning nucleotides 132389-131130, wherein Seq.ID 32 can be provided with a T7-polymerase sequence, methods using said oligonucleotides for the detection of EBV, as well as a test kit comprising these oligonucleotides.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/EP 99/01392

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323569 A	25-11-1993	US 5496698 A	05-03-1996
		AU 4221593 A	13-12-1993
		AU 687736 B	05-03-1998
		AU 4222993 A	13-12-1993
		CA 2135646 A	25-11-1993
		EP 0642589 A	15-03-1995
		JP 8500481 T	23-01-1996
		MX 9302726 A	31-08-1994
		US 6017756 A	25-01-2000
		US 5622854 A	22-04-1997
		US 5693535 A	02-12-1997
		US 5972704 A	26-10-1999
		US 5610054 A	11-03-1997
		US 5869253 A	09-02-1999
		US 5795778 A	18-08-1998
		US 5972699 A	26-10-1999
		US 5525468 A	11-06-1996
		US 5646020 A	08-07-1997
		US 5686599 A	11-11-1997
		US 5804683 A	08-09-1998
		US 5631360 A	20-05-1997
		US 5977343 A	02-11-1999
		US 5831071 A	03-11-1996
		US 5891684 A	06-04-1999
		US 5879938 A	09-03-1999
		US 5767263 A	16-06-1998
		US 5672511 A	30-09-1997
WO 9737669 A	16-10-1997	US 5837854 A	17-11-1998
		AU 2801497 A	29-10-1997
JP 05309000 A	22-11-1993	NONE	
WO 9307882 A	29-04-1993	AU 2886292 A	21-05-1993
		NZ 244820 A	26-01-1994
WO 9804746 A	05-02-1998	US 5942391 A	24-08-1999
		EP 0915991 A	19-05-1999
WO 9732036 A	04-09-1997	AU 1795297 A	16-09-1997
EP 0628568 A	14-12-1994	DE 4344742 A	15-12-1994
		JP 7184696 A	25-07-1995
		US 5639609 A	17-06-1997
EP 0574048 A	15-12-1993	AU 666920 B	29-02-1996
		AU 3515293 A	16-09-1993
		CA 2092680 A	14-09-1993
		FI 931109 A	14-09-1993
		JP 6090787 A	05-04-1994
		US 5424398 A	13-06-1995
		US 6008327 A	28-12-1999
		ZA 9301797 A	30-09-1993
WO 9311267 A	10-06-1993	AU 3089892 A	28-06-1993
DE 19627932 A	15-01-1998	WO 9802584 A	22-01-1998

Form PCT/ISA/210 (patent family annex) (July 1992)